文献速递认知障碍与痴呆

抗淀粉样蛋白治疗资格评估人群的混合病理与认知结局:社区尸检研究

Mixed Pathologies and Cognitive Outcomes in Persons Considered for Anti-Amyloid Treatment Eligibility Assessment: A Community-Based Study.
PubMed 文献 · Neurology · 2025-08-18

该社区尸检研究纳入428例符合抗淀粉样蛋白治疗资格评估的老年人,94%有阿尔茨海默病神经病理改变,仅26%无LATE-NC、路易体或梗死。缠结和小动脉硬化与整体认知下降更快相关,缠结和LATE-NC与情景记忆下降更快相关,提示共存病理可驱动认知下降。

要点

  • 符合抗淀粉样蛋白治疗资格的社区老年人中混合病理常见,仅26%为单纯ADNC。
  • 缠结和小动脉硬化与整体认知下降更快相关。
  • 缠结和LATE-NC与情景记忆下降更快相关,提示共存病理影响疗效。

核心结论

  • 在考虑抗淀粉样蛋白治疗资格评估的社区老年人中,混合病理常见,除Aβ外缠结、LATE-NC和血管病理驱动认知下降。

研究设计与样本

  • 社区尸检研究纳入428例老年人(死亡时平均年龄91岁,70%女性),符合MMSE≥20、MCI或轻度阿尔茨海默痴呆临床诊断及尸检Aβ病理提示PET阳性。

主要发现

  • 94%有ADNC,仅26%无LATE-NC、路易体或梗死,68%有ADNC伴至少一种共存病理,ADNC+梗死与ADNC+LATE-NC同样常见。
  • 缠结和小动脉硬化均与整体认知下降更快相关。
  • 缠结和LATE-NC与情景记忆下降更快相关,ADNC与语义记忆下降更快相关且Aβ进一步与工作记忆下降相关,动脉粥样硬化与知觉速度下降更快相关。
  • 梗死和路易体与整体认知或任何认知域下降无关。

临床怎么用

  • 对符合抗淀粉样蛋白治疗资格评估的老年人,应认识共存病理对认知下降的独立影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Despite the capability of anti-amyloid monoclonal antibodies to lower β-amyloid (Aβ) brain levels, there is thus far limited clinical efficacy on cognitive outcomes. Among individuals with mild cognitive impairment (MCI) or mild-stage dementia, the cognitive impact of other brain pathologies may limit efficacy of anti-amyloid drugs. This study examined the burden and cognitive associations of mixed brain pathologies among autopsied persons who would have been considered as patients to undergo anti-amyloid treatment eligibility assessment. METHODS: Eligibility was defined based on a Mini-Mental State Examination score ≥20, a clinical diagnosis of MCI or mild-stage Alzheimer dementia, and a level of Aβ pathology at autopsy indicative of having a positive amyloid PET scan (Consortium to Establish a Registry for Alzheimer's Disease score ≥moderate). The number and types of copathologies were examined. Mixed-effects models were used to examine the association of Aβ, tangles, limbic predominant age-related transactive response DNA-binding protein 43 encephalopathy neuropathologic changes (LATE-NC), infarcts, Lewy bodies (LBs), and vessel diseases, with the rate of cognitive decline. RESULTS: Among 428 older autopsied persons (mean age at death = 91 years, 70% women) considered for anti-amyloid treatment eligibility assessment, 58% had MCI and 42% had mild-stage Alzheimer dementia. Although the majority (94%) had a pathologic diagnosis of Alzheimer disease neuropathologic changes (ADNC), only 26% had ADNC without LATE-NC, LB, or infarcts. The majority (68%) had ADNC with ≥1 copathology with ADNC + infarcts and ADNC + LATE-NC being equally common. In mixed-effects models, tangles and arteriolosclerosis were both associated with a faster rate of global cognitive decline. Separately, tangles and LATE-NC were associated with a faster decline in episodic memory, ADNC was associated with faster decline in semantic memory with Aβ being further associated with decline in working memory, and atherosclerosis was associated with a faster decline in perceptual speed. Infarcts and LBs were not associated with decline in global cognition or any cognitive domain. DISCUSSION: Mixed pathologies are common among community-dwelling older persons considered for anti-amyloid treatment eligibility assessment. Beyond Aβ, tangles, LATE-NC, and vessel pathologies drive cognitive decline in this group of individuals, especially episodic memory decline. These findings suggest that, even among those eligible for anti-amyloid therapies, substantial cognitive decline may occur because of the presence of coexisting pathologies.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Kapasi A, James BD, Yu L, et al. Mixed Pathologies and Cognitive Outcomes in Persons Considered for Anti-Amyloid Treatment Eligibility Assessment: A Community-Based Study. Neurology. 2025. PMID: 40825161. doi:10.1212/WNL.0000000000214004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。